Polymorphs, or different crystalline forms of the same drug, can be selected for distinct properties and patented. A recent ...

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...

<p>On this week&#39;s episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an ...

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in Big Pharma and biotech culture and expectations to be successful.

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical issues and the risk that AI may ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS ...

Trade secrets protect innovation by keeping that innovation secret. But trade secret protection is lost once the trade secret becomes known to the public. Biotechs should have a strategic plan for ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.